Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 137

1.

Risky Alcohol Use: The Impact on Health Service Use.

Miquel L, Manthey J, Rehm J, Vela E, Bustins M, Segura L, Vieta E, Colom J, Anderson P, Gual A.

Eur Addict Res. 2018 Oct 3;24(5):234-244. doi: 10.1159/000493884. [Epub ahead of print]

PMID:
30282079
2.

New Alcohol Biomarkers. New challenges.

Barrio P, Wurst FM, Gual A.

Alcohol Alcohol. 2018 Nov 1;53(6):762-763. doi: 10.1093/alcalc/agy064. No abstract available.

PMID:
30204846
3.

Publisher Correction: Alcoholic liver disease.

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H.

Nat Rev Dis Primers. 2018 Aug 28;4(1):18. doi: 10.1038/s41572-018-0021-8.

PMID:
30154473
4.

A Survey on the Medical Use of Cannabis in Europe: A Position Paper.

Bramness JG, Dom G, Gual A, Mann K, Wurst FM.

Eur Addict Res. 2018;24(4):201-205. doi: 10.1159/000492757. Epub 2018 Aug 22.

PMID:
30134238
5.

Alcoholic liver disease.

Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H.

Nat Rev Dis Primers. 2018 Aug 16;4(1):16. doi: 10.1038/s41572-018-0014-7. Review. Erratum in: Nat Rev Dis Primers. 2018 Aug 28;4(1):18.

PMID:
30115921
6.

Quality of life role in risky alcohol use research: should it be a more relevant outcome in any study?

López-Pelayo H, Oliveras C, Segura L, Colom J, Díaz E, Wallace P, Gual A.

Adicciones. 2018 Jul 13;0(0):1098. doi: 10.20882/adicciones.1098. [Epub ahead of print] English, Spanish.

7.

Role of Alcohol and Drug Detection by Regular Urine Sample Testing in pre-transplant evaluation for Alcohol Liver Disease.

López Pelayo H, Altamirano J, López E, Barrio P, López A, Gual A, Lligoña A.

Adicciones. 2018 Jul 20;0(0):1121. doi: 10.20882/adicciones.1121. [Epub ahead of print] English, Spanish.

8.

A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?

Barrio Giménez P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.

Adicciones. 2018 Jul 13;0(0):1046. doi: 10.20882/adicciones.1046. [Epub ahead of print] English, Spanish.

9.

Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level.

van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch OM, Mann K, Maremmani I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, Simon N, Söderpalm B, Sommer WH, Walter H, Spanagel R.

Addict Biol. 2018 Jul;23(4):969-986. doi: 10.1111/adb.12645.

PMID:
30043457
10.

Quantitative Criteria to Screen for Cannabis Use Disorder.

Casajuana C, López-Pelayo H, Miquel L, Balcells-Oliveró MM, Colom J, Gual A.

Eur Addict Res. 2018;24(3):109-117. doi: 10.1159/000488346. Epub 2018 Jun 27.

PMID:
29949807
11.

Optimizing the delivery of interventions for harmful alcohol use in primary healthcare: an update.

Segura L, Anderson P, Gual A.

Curr Opin Psychiatry. 2018 Jul;31(4):324-332. doi: 10.1097/YCO.0000000000000435.

PMID:
29846264
12.

Reducing the health risks derived from exposure to addictive substances.

Anderson P, Gual A, Rehm J.

Curr Opin Psychiatry. 2018 Jul;31(4):333-341. doi: 10.1097/YCO.0000000000000432.

PMID:
29746421
13.

How does Economic Recession Affect Substance Use? A Reality Check with Clients of Drug Treatment Centres.

Bruguera P, Reynolds J, Gilvarry E, Braddick F, Marath-Veettil AL, Anderson P, Mielecka-Kubien Z, Kaner E, Gual A.

J Ment Health Policy Econ. 2018 Mar 1;21(1):11-16.

PMID:
29643264
14.

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver.

J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018. Epub 2018 Apr 5. No abstract available.

PMID:
29628280
15.

Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?

Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.

Clin Drug Investig. 2018 Apr;38(4):387-388. doi: 10.1007/s40261-018-0625-5. No abstract available.

PMID:
29480453
16.

Effectiveness of a Specialized Brief Intervention for At-risk Drinkers in an Emergency Department: Short-term Results of a Randomized Controlled Trial.

Bruguera P, Barrio P, Oliveras C, Braddick F, Gavotti C, Bruguera C, López-Pelayo H, Miquel L, Segura L, Colom J, Ortega L, Vieta E, Gual A.

Acad Emerg Med. 2018 May;25(5):517-525. doi: 10.1111/acem.13384. Epub 2018 Apr 2.

PMID:
29418049
17.

Alcohol, tobacco and health care costs: a population-wide cohort study (n = 606 947 patients) of current drinkers based on medical and administrative health records from Catalonia.

Miquel L, Rehm J, Shield KD, Vela E, Bustins M, Segura L, Colom J, Anderson P, Gual A.

Eur J Public Health. 2018 Aug 1;28(4):674-680. doi: 10.1093/eurpub/ckx236.

PMID:
29325000
18.

Filling the gap between lab and clinical impact: An open randomized diagnostic trial comparing urinary ethylglucuronide and ethanol in alcohol dependent outpatients.

Barrio P, Teixidor L, Ortega L, Lligoña A, Rico N, Bedini JL, Vieta E, Gual A.

Drug Alcohol Depend. 2018 Feb 1;183:225-230. doi: 10.1016/j.drugalcdep.2017.11.015. Epub 2017 Dec 27.

PMID:
29291550
19.

Scaling-up primary health care-based prevention and management of heavy drinking at the municipal level in middle-income countries in Latin America: Background and protocol for a three-country quasi-experimental study.

Anderson P, O'Donnell A, Kaner E, Gual A, Schulte B, Pérez Gómez A, de Vries H, Natera Rey G, Rehm J.

Version 3. F1000Res. 2017 Mar 23 [revised 2017 Jan 1];6:311. doi: 10.12688/f1000research.11173.3. eCollection 2017.

20.

Barriers to implement screening for alcohol consumption in Spanish hypertensive patients.

Miquel L, López-Pelayo H, Nuño L, Arbesú JÁ, Zarco J, Manthey J, Rehm J, Gual A.

Fam Pract. 2018 May 23;35(3):295-301. doi: 10.1093/fampra/cmx107.

PMID:
29106526

Supplemental Content

Loading ...
Support Center